Latest Payments News

Nexalis Therapeutics has locked in a $53 million non-dilutive funding facility with Point8 Capital, replacing its previous lender and supporting three clinical programs targeting breakthrough cancer pain, panic disorder, and treatment-resistant depression.

Beonic Ltd (ASX:BEO) has initiated a $3 million pro-rata renounceable entitlement offer at $0.08 per share, partially underwritten by Alpine Capital, to shore up working capital and repay shareholder loans. The offer carries potential dilution of 35.7% for non-participating shareholders and may increase the Thorney Group's voting power significantly.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

Select Harvests delivered a 33% rise in underlying NPAT despite a wet harvest and higher costs, announcing a fully franked interim dividend and a 10% on-market share buy-back.

Acrux has amended its licensing agreement with Gedeon Richter to bring its Estradiol spray Lenzetto® to Australia, unlocking up to AUD 5.4 million in milestone payments and addressing a critical shortage in Menopause Hormone Therapy products.

HealthCo Healthcare & Wellness REIT has reached a government-backed agreement with Bethesda Health Care to operate the Mount Private Hospital, marking a significant step in resolving Healthscope-related uncertainties and ensuring long-term portfolio stability.

Zoono Group has secured its first major commercial orders worth NZ$600,000 from Sharpak under an exclusive UK soft fruits packaging contract, marking a key step in scaling its antimicrobial coating technology in international markets.

Promisia Healthcare reported a robust 29% increase in operating revenue for FY26, alongside a new dividend policy tied to operating free cash flow, setting the stage for continued growth in FY27.

Klevo Rewards takes a major step in building a regulated crypto-financial platform by partnering with Bybit and proposing key acquisitions to expand Fly Wallet’s digital asset and credit capabilities.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Cosmos Exploration has finalised its acquisition of EAU Lithium, issuing 108 million shares to former EAU shareholders and appointing James Durrant as Chairman to drive its Bolivian lithium ambitions.

Vista Group International has secured a five-year contract to transition Cinemex’s Mexican cinema circuit back to its technology platform, expanding on last year’s US rollout success.